DDInter127 DDInter1055
Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rosuvastatin
Rosuvastatin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rosuvastatin
Rosuvastatin {u} (Compound) causes {v} (Side Effect) Neuropathy peripheral
Neuropathy peripheral {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) upregulates {v} (Gene) GPATCH8
GPATCH8 {u} (Gene) is upregulated by {v} (Compound) Levofloxacin
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gemtuzumab ozogamicin
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacarbazine
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gemtuzumab ozogamicin
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levofloxacin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Levofloxacin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Levofloxacin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Gemtuzumab ozogamicin and Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine and Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Gemtuzumab ozogamicin and Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)